The global defense emergency medicine market is expected to grow at a CAGR of around 19.4% from 2020 to 2027 and anticipated to reach the market value of around US$ 13,832 Mn by 2027.
Defense emergency medicines are used for care and management for soldiers in the warfare with proper supply of emergency medical aids in urgent situation such as sudden physical injury, respiratory and cardiac disorders, infections, and among others. The diagnostic emergency medicine supplies involve ventilators, diagnostic kits, bandages, dressings, thermometers and personal protective equipment (PPE), and others. The defense emergency medical supply is evolving day by day. There is a drastic shift from a simple transportation system (ambulance service) to a system in which actual medical care occurred beyond transportation. The ultimate goal of defense emergency medical supplies is to provide treatment to the soldiers at warfare with proper alignment for timely removal of the patient and shifting to the next point of definitive care that is most likely to be a casualty at hospitals or another place where physicians are available.
High government involvement
World Health Organization (WHO) has standardized medicines and medical supplies required in emergencies to offer swift, efficient, and effective response to the need for medicine and medical supplies in defense. This has resulted in supply of standard, pre-packed kits that are managed to meet priority health needs in case of emergency. Such factors fuel the growth of defense emergency medicine market. WHO uses standardized medical kits for diagnosis in different emergency situations such as unintentional injuries caused during wars. These medical supplies are used as an initial supply of primary healthcare facilities when compared with normal system where normal provision system has broken down. Additionally, a collaboration of governing bodies will further enhance growth of defense emergency medicine market. In December 2018, The United States Food and Drug Administration (USFDA) and Department of Disease (DoD) has signed Memorandum of Understanding (MoU) regarding medical product development and assessment. This collaboration enhances the supply of advanced medical products in support of American military personnel. This builds upon the work of both agencies to foster and prioritize the efficient development of safe and effective medical products that are intend to save lives of American service members.
Collaborations an acquisition enhances the growth of defense emergency medicine market
Collaboration between the governing bodies offers lucrative opportunities for the growth of defense emergency medicine market in terms of emergency use authorization of the products. The collaboration between FDA and DoD is working closely to expand opportunities regarding availability of medical products, specifically those products intending to treat injuries in battlefield settings. In 2017, emergency use authorization for French freeze dried plasma was approved. Such close collaborations assist the governing bodies to target and address more efficiently immediate product development and supply in most streamlined manner. Further, FDA and DoD is looking forward to additional partnership opportunities under the MoU.
Rigorous product approvals will witness stupendous growth opportunities for defense emergency medicine market
In July 2018, FDA grated Emergency Use Authorization (EUA) for DoD emergency use of pathogen-reduced leukocyte depleted freeze dried plasma manufactured by Centre de Transfusion Sanguine des Armées (often referred to as French freeze-dried Plasma) This reflects the importance of both DoD and FDA for efficiently prioritizing and expediting availability of potentially life saving biological products essential for urgent care of military personnel, specifically for those in potential life battlefield settings. In July 2018, FDA approved atropine autoinjector device as a medical countermeasure on chemical nerve agent exposure. This drug device product was developed in partnership with Joint Program Executive Officer for Chemical, Radiological, Biological, and Nuclear Defense. In August 2018, FDA approved first prophylactic drug for malaria in over 18 years, tafenoquine (Arakoda). This drug was developed in partnership with US Army Medical Research and Materiel Command. Additionally, In October 2018, FDA issued draft guidance that supports the development and eventual approval of dried plasma products. Since these types of plasma do not required to be stored frozen and can be reconstituted and administered quickly can be effective for military personnel in remote areas without freezers and other supportive equipments.
Defense emergency medicine market is segmented based on type, application, and end-user. Type segment is divided as diagnostic and monitoring equipment, wound care supplies, patient handling equipment, and among others. Diagnostic and monitoring equipment is further segmented as ECG monitor, blood pressure monitors, pulse oximetry, and others. By wound care the market is sub-segmented as dressings and bandages, sutures and staples, and among others. By patient handling equipment, market is segmented as medical beds, wheelchairs and scooters, patient lifting equipment, and others. Based on application, the market is segmented as cardiac care, respiratory care, trauma, and others. By end-use, the market is segmented into hospitals, ambulatory surgical, research and diagnostic laboratories, and others.
North America will dominate the defense emergency medicine market globally followed by Asia Pacific. This is due to high government involvement coupled with initiative in the US. Additionally, the department of defense in the US is preparing for next major step in consolidating military hospitals and clinics under one roof that is considered as one of the largest organizational changes within the US military in decades. For the first time in military history of US a single agency name "Defense Health Agency (DHA)" will be responsible for the entire healthcare coupled with 9.5 million beneficiaries. The preliminary driver responsible for such a change is the National Defense Authorization Act of 2017. Congress mandated that a single agency is responsible for the administration and management of all military hospitals and clinics to sustain and improve operational medical force readiness, improve beneficiaries, access to care, improve health outcomes through emergency handling, and eliminate redundancies in medical cost and overhead expense of three separate service run systems.
Asia Pacific is also gaining fast pace in the defense emergency medicine regional market owing to high procurement strategies related to medical equipments. Moreover, government of India is planning to spend US$ 130 Bn on military modernization in next 5 years to achieve self reliance in defense production and emergency medical supplies (EMS) as a key target for the Government of India.
Key companies profiled in this report involve Stryker, Medtronic plc, Asahi Kasei Corporation, Koninklijke Phillips N.V., GE Healthcare, Smith & Nephew, Cardinal Health, Smiths Medical, Becton & Dickinson Company, Johnson & Johnson, B. Braun Melsungen AG, Abbott Laboratories, Bayer Corporation, The 3M Company and among others.
Market By Type
Diagnostics and Monitoring Equipment
Wound Care Supplies
Patient Handling Equipment
Market By Application
Market by End-use
Ambulatory Surgical Centers
Research and Diagnostic Laboratories
Market By Geography
Middle East & Africa
Defense Emergency Medicine is expected to reach a market value of around US$ 13,832 Mn by 2027.
The defense emergency medicine market is expected to grow at a CAGR of around 19.4% from 2020 to 2027.
Based on type, patient handling equipment is the leading segment in the overall market.
High government involvement is the preliminary factor that drives the demand for defense emergency medicine market.
Stryker, Medtronic plc, Asahi Kasei Corporation, Koninklijke Phillips N.V.,GE Healthcare, Smith & Nephew, Cardinal Health, Smiths Medical, Becton & Dickinson Company, Johnson & Johnson, B. Braun Melsungen AG, Abbott Laboratories, Bayer Corporation, The 3M Company and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years